H. Lundbeck A/S: Revenue from Vyepti for [Migraine Prophylaxis] Increases by 57% and Allows for Forecast Revision!

H. Lundbeck A/S is an internationally operating pharmaceutical company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of drugs for treating central nervous system (CNS) disorders. The focus includes the search for treatment solutions for neurological and psychiatric conditions such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, epilepsy, and rare neurological disorders. For this purpose, the company has already developed several products such as Brintellix / Trintellix...